Eris Lifesciences Limited (NSE:ERIS)
India · Delayed Price · Currency is INR 1,378.40
-20.60 (-1.47%)
Jun 1, 2026, 3:29 PM IST
Eris Lifesciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 6,195 | 3,518 | 3,921 | 3,822 | 4,061 |
Depreciation & Amortization | 2,795 | 3,124 | 1,797 | 1,144 | 626.21 |
Other Amortization | - | 30.6 | 28.2 | 26.58 | 20.84 |
Loss (Gain) From Sale of Assets | 0.4 | 9.2 | 21.4 | 20.18 | 42.54 |
Loss (Gain) From Sale of Investments | -6.8 | -30 | -93.8 | -69.33 | -167.61 |
Loss (Gain) on Equity Investments | -0.9 | -0.6 | - | - | - |
Stock-Based Compensation | 80 | 91.3 | 7.5 | 31.21 | 13.55 |
Provision & Write-off of Bad Debts | -107 | - | - | 0.67 | 0.02 |
Other Operating Activities | 1,004 | 2,648 | 166.8 | -302.45 | -515.03 |
Change in Accounts Receivable | -2,103 | -91.1 | -570.9 | -1,171 | -204.8 |
Change in Inventory | -1,007 | -943.6 | -169.4 | 47.44 | -234.45 |
Change in Accounts Payable | -31.6 | 679.4 | 909.8 | -104.97 | 151.59 |
Change in Other Net Operating Assets | -1,439 | 1,615 | -1,157 | -526.45 | -11.35 |
Operating Cash Flow | 5,380 | 10,650 | 4,860 | 2,917 | 3,783 |
Operating Cash Flow Growth | -49.48% | 119.13% | 66.59% | -22.88% | 0.77% |
Capital Expenditures | -2,969 | -1,550 | -1,292 | -8,414 | -1,210 |
Sale of Property, Plant & Equipment | 0.9 | 3.7 | - | 1.37 | 7.58 |
Cash Acquisitions | -100 | -11,690 | -5,668 | -6,555 | - |
Investment in Securities | -284.3 | -484.3 | 484.1 | 4,904 | -1,881 |
Other Investing Activities | -342.6 | 12,923 | -12,053 | 35.61 | 49.32 |
Investing Cash Flow | -3,695 | -799.7 | -18,545 | -9,821 | -3,196 |
Short-Term Debt Issued | 530 | - | - | - | - |
Long-Term Debt Issued | 1,173 | 14,364 | 16,231 | 11,678 | 450.01 |
Total Debt Issued | 1,703 | 14,364 | 16,231 | 11,678 | 450.01 |
Long-Term Debt Repaid | -2,950 | -18,424 | -1,603 | -3,587 | -115.01 |
Total Debt Repaid | -2,950 | -18,424 | -1,603 | -3,587 | -115.01 |
Net Debt Issued (Repaid) | -1,247 | -4,059 | 14,628 | 8,091 | 335 |
Issuance of Common Stock | 44.8 | 72.2 | 45.4 | 22.78 | 71.96 |
Common Dividends Paid | - | -1,001 | - | -999.11 | -816.23 |
Other Financing Activities | -1,933 | -3,826 | -875.7 | -234.3 | -37.72 |
Financing Cash Flow | -3,135 | -8,813 | 13,798 | 6,880 | -446.99 |
Miscellaneous Cash Flow Adjustments | - | 17.7 | 269.6 | 74.9 | - |
Net Cash Flow | -1,450 | 1,055 | 382.3 | 51.52 | 139.55 |
Free Cash Flow | 2,411 | 9,100 | 3,569 | -5,497 | 2,572 |
Free Cash Flow Growth | -73.50% | 155.01% | - | - | -26.42% |
Free Cash Flow Margin | 7.74% | 31.61% | 17.92% | -33.08% | 19.40% |
Free Cash Flow Per Share | 17.62 | 66.77 | 26.21 | -40.37 | 18.93 |
Cash Interest Paid | 1,933 | 1,451 | 773 | 234.3 | 38.5 |
Cash Income Tax Paid | 1,244 | 978.8 | 1,008 | 772.08 | 832.85 |
Levered Free Cash Flow | -301.18 | 6,527 | 2,357 | -6,892 | 1,623 |
Unlevered Free Cash Flow | 903.01 | 7,973 | 2,887 | -6,729 | 1,649 |
Change in Working Capital | -4,580 | 1,260 | -987.4 | -1,755 | -299.01 |